Jelmyto Demonstrates Significant Recurrence-Free Survival Rate at Three Years in Patients with Low-Grade Upper Tract Urothelial Cancer
Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with Jelmyto.